Avalo Therapeutics (AVTX) Assets Average (2015 - 2026)
Avalo Therapeutics (AVTX) posted Assets Average of $108.2 million for Q1 2026, down 10.44% on a QoQ basis from $120.8 million in Q4 2025, and down 25.21% year-over-year from $144.6 million in Q1 2025.
Avalo Therapeutics (AVTX) Assets Average (2015 - 2026) Analysis & Trends
Avalo Therapeutics' Assets Average history runs 12 years deep, the most recent figure standing at $108.2 million for Q1 2026.
- Quarterly Assets Average fell 25.21% year-over-year to $108.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.2 million (down 25.21% YoY) and the FY2025 annual result came in at $133.6 million, up 55.59% from the prior year.
- Assets Average was $108.2 million for Q1 2026 at Avalo Therapeutics, down from $120.8 million in the prior quarter.
- Across five years, Assets Average topped out at $144.6 million in Q1 2025 and bottomed at $25.1 million in Q4 2023.
- A 5-year average of $79.6 million and a median of $72.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average sank 60.18% — and 2024, when it soared 395.77%.
- Avalo Therapeutics' Assets Average stood at $35.0 million in 2022, then dropped by 28.11% to $25.1 million in 2023, then soared by 395.77% to $124.6 million in 2024, then decreased by 3.06% to $120.8 million in 2025, then retreated by 10.44% to $108.2 million in 2026.
- Business Quant data shows AVTX's Assets Average at $108.2 million in Q1 2026, $120.8 million in Q4 2025, and $125.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 108.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 108.17 Mn |
| Dec 31, 2025 | 120.78 Mn |
| Sep 30, 2025 | 125.84 Mn |
| Jun 30, 2025 | 132.55 Mn |
| Mar 31, 2025 | 144.63 Mn |
| Dec 31, 2024 | 124.59 Mn |
| Sep 30, 2024 | 103.38 Mn |
| Jun 30, 2024 | 116.02 Mn |
| Mar 31, 2024 | 72.36 Mn |
| Dec 31, 2023 | 25.13 Mn |
| Sep 30, 2023 | 26.75 Mn |
| Jun 30, 2023 | 30.24 Mn |
| Mar 31, 2023 | 34.80 Mn |
| Dec 31, 2022 | 34.96 Mn |
| Sep 30, 2022 | 34.39 Mn |
| Jun 30, 2022 | 47.06 Mn |
| Mar 31, 2022 | 71.06 Mn |
| Dec 31, 2021 | 87.79 Mn |
| Sep 30, 2021 | 79.72 Mn |
| Jun 30, 2021 | 63.72 Mn |